SolmazSahebjamMD
Oncology • Washington, DCHematologic Oncology, Neuro-Oncology
Director of Neuro-oncology Program in National Capital Region, Deputy Director of Clinical Research in National Capital Region, Associate Professor (PAR) of Oncology
Dr. Sahebjam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Johns Hopkins School of Medicine
Washington, DC 20016Phone+1 202-537-4000- Is this information wrong?
Education & Training
St Vincent HospitalResidency, Internal Medicine, 2006 - 2008
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2005 - 2006
Iran University of Medical SciencesClass of 2000
Certifications & Licensure
FL State Medical License 2013 - 2025
MD State Medical License 2023 - 2025
DC State Medical License 2022 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Royal College of Physicians and Surgeons of CanadaBoard of Internal Medicine
- Royal College of Physicians and Surgeons of CanadaBoard of Medical Oncology
Clinical Trials
- A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
- Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
- Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
- Join now to see all
Publications & Presentations
PubMed
- Towards gender equity in neuro-oncology.Leeper, H., Sahebjam, S.> ;Neuro-Oncology Practice. 2024 Feb 1
- Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.Davis, E., Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Powell, Bruno Bastos, Eli...> ;Clinical Cancer Research. 2024 Feb 1
- Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram> ;NPJ Breast Cancer. 2023 Nov 17
- Join now to see all
Journal Articles
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaDavid A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
Authored Content
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
